Used in research and development for targeting nerve growth factor (NGF) pathways, this antibody has potential therapeutic applications in chronic pain conditions such as osteoarthritis and lower back pain. By inhibiting NGF activity, it helps modulate pain signaling in sensory neurons, offering a non-opioid approach to pain management. It has been investigated in clinical trials to assess efficacy and safety in patients with pain conditions unresponsive to conventional treatments. Additionally, it serves as a reference standard in immunoassays and bioanalytical testing for evaluating anti-NGF therapeutics.